Diabetes patients likely to develop macula oedema after cataract surgery

Article

Patients with Type 2 diabetes undergoing cataract surgery are twice as likely to develop macula oedema than patients without diabetes.

Patients with Type 2 diabetes undergoing cataract surgery are twice as likely to develop macula oedema than patients without diabetes, according to Anna Wikberg-Matsson and colleagues from Uppsala University, Sweden.

A consecutive, prospective, randomized study followed two groups of patients, 40 with simplex retinopathy and 40 healthy patients, after cataract surgery. Preoperative visual acuity (VA) in the diabetes group was 0.4 and 0.5 in the control group.

At six-weeks follow-up, the VA was 0.5 and 0.8 in the diabetes and the control group, respectively whilst at six months the VA was 0.77 and 0.9, respectively. Macula oedema was seen in 77% of the diabetes patients at the six-week time point and in 30% of the controls. At six weeks, macula volume had increased in both groups but there was a significant difference between the two groups (p<0.05).

It was concluded by the researchers that patients with Type 2 diabetes are twice as likely to develop macula oedema following cataract surgery than healthy subjects.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.